Funding · 13 June 2026Zumutor Biologics$7.3 Mn (₹70 Cr)Develops immunotherapy drugs for cancerzumutor.com ↗
FundingHealthcare & Life Sciences
Zumutor Biologics raises $7.3 million in Pre-Series B funding
By Abha Lohia · Editor ·
Zumutor Biologics: revenue and funding and every story →
Series BBengaluruFounded 2013
- Zumutor develops immunotherapy drugs that activate natural killer cells to attack tumours
- The company raised $7.3 million in Pre-Series B funding from Premji Invest, Accel, Bharat Innovation Fund, and angels Ashish Kacholia and Raj Dandu
- Funds will support global Phase 2 studies of its lead drug ZM008 starting in India
What happened
- Zumutor Biologics has raised $7.3 million in a new funding round.
- The investment was led by Premji Invest, a new participant in the deal.
- Existing investors Accel and Bharat Innovation Fund also participated in this round.
- Angel investors Ashish Kacholia and Raj Dandu joined the funding as well.
- The company plans to complete US FDA Phase 1 clinical studies of its drug ZM008.
- Funds will initiate Phase 1B expansion cohorts and global Phase 2 studies including in India.
- This follows an earlier Series A4 round of $6.2 million in 2021.
- Human trials for ZM008 began in 2024 showing early signals in difficult-to-treat tumour types.
Why it matters
- The funding supports the company's push into global Phase 2 clinical studies.
- It aligns with the government's biopharma SHAKTI scheme worth ₹10,000 crore.
- India's bioeconomy is projected to reach $300 billion by 2030.
The business
- Zumutor develops immunotherapy drugs that activate natural killer cells to attack tumours.
- Its lead program is ZM008, described as a first-in-class NK cell checkpoint therapy.
- The company utilizes two proprietary Antibody Engineering Platforms targeting innate immunity.
- These platforms specifically target the tumor microenvironment to enhance drug efficacy.
- The company is headquartered in the US with an R&D laboratory in Bengaluru.
- Founding CEO Kavitha Iyer Rodrigues leads the company since its establishment in 2013.
- Chief Scientific Officer Maloy Ghosh oversees the scientific development of therapies.
- The company focuses on treating difficult-to-treat tumour types through innovative mechanisms.
The founders
KI
Kavitha Iyer Rodrigues
Founder and CEO- Founded Zumutor Biologics in 2013.
- Leads the company's strategic direction and operations.
- Oversees the development of immunotherapy drugs.
Who put in money
- Premji Invest lead — New investor participating in the Series B round.
- Accel existing — Existing investor continuing support in the current round.
- Bharat Innovation Fund existing — Existing investor participating in the funding round.
In numbers
₹4.6 CrTotal Revenue FY25 · 2025
₹8.6 CrTotal Expenses FY25 · 2025
₹-3.9 CrProfit After Tax FY25 · 2025
-84.2%Net Profit Margin FY25 · 2025
₹58.6 CrTotal Assets FY25 · 2025
What happens next
- Complete US FDA Phase 1 clinical study of ZM008 monotherapy and combination regimens.
- Initiate Phase 1B expansion cohorts for further clinical evaluation.
- Launch global Phase 2 studies including trials in India.
Earlier rounds
- 2021 · Series A4 · $6.2 Mn · led by Siana Capital
Up against
StrainX BioworksCellogen Therapeutics
Words to know
- Immunotherapy
- Treatment that uses the body's immune system to fight diseases like cancer.
- Natural Killer (NK) Cells
- A type of white blood cell that attacks tumours and infected cells.
- Phase 1 Clinical Study
- Early-stage research testing safety and dosage in humans.
- First-in-class
- A drug with a novel mechanism of action not seen before.
The numbers around it
Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Zumutor Biologics → · All startup news on 13 June 2026 →
Is this Zumutor Biologics? Get your “Featured on StopDown” badge →